Armata Pharmaceuticals (ARMP) to Post Quarterly Earnings on Tuesday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $0.40 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The business had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.74 million. On average, analysts expect Armata Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Armata Pharmaceuticals Trading Up 8.4%

Shares of NYSEAMERICAN:ARMP traded up $0.42 during midday trading on Tuesday, hitting $5.47. 24,702 shares of the stock were exchanged, compared to its average volume of 90,120. The stock has a market cap of $200.99 million, a P/E ratio of -0.70 and a beta of 1.30. Armata Pharmaceuticals has a twelve month low of $2.36 and a twelve month high of $16.34. The company has a 50 day moving average price of $6.18 and a 200-day moving average price of $8.22.

Institutional Trading of Armata Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARMP. Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals during the fourth quarter worth about $284,000. OMERS ADMINISTRATION Corp acquired a new stake in Armata Pharmaceuticals during the fourth quarter worth approximately $177,000. Renaissance Technologies LLC grew its stake in Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after acquiring an additional 27,200 shares during the period. Millennium Management LLC acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at $164,000. Finally, Jane Street Group LLC acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at $108,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.